Terazosin: uses, dosing, side effects & brands
Terazosin is an alpha-adrenergic blocker sold in the U.S. under 2 brand and generic names, for hypertension, prostatic hyperplasia and urinary retention. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Drug class
- Alpha-Adrenergic Blocker
- Treats (across its forms)
- Hypertension, Prostatic Hyperplasia and Urinary Retention
- Available as
- Tablet · Capsule · Solution
- Sold as
- 2 products — Hytrin and Tezruly
- Prescription?
- Prescription only
- Generic available?
- Not in our catalog
- What the pharmacy pays
- about $4 for a 30-count supply — not your price
Get treated for Terazosin conditions online
Licensed online providers — consult & get prescribed if eligible.
Advertising disclosure: We may earn a commission, at no extra cost to you. This never affects our ratings. Details
How Tezruly is dosed
From the FDA label for Tezruly (application NDA218139). Other terazosin products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
For the treatment of BPH: Initiate therapy at 1 mg orally once daily at bedtime. Titrate the dose upwards step-wise from 2 mg to 10 mg once daily. Doses of 10 mg once daily are generally required for a clinical response. Data is insufficient to support doses greater than 20 mg once daily. (2.1) For the treatment hypertension: Initiate therapy at 1 mg orally once daily at bedtime. Usual recommended dose range is 1 mg to 5 mg once daily. If response is substantially diminished at 24 hours, increase the dose or use twice daily. Dose may be titrated as needed up to 20 mg once daily. (2.2) If terazosin is discontinued for more than a few days, restart using the initial dosing regimen. (2.1) 2.1 Recommended Dosage for Benign Prostatic Hyperplasia Initial Dose: 1 mg orally once daily at bedtime. This dose should not be exceeded as an initial dose. Closely follow patients during initial administration in order to minimize the risk of severe hypotensive response, including syncope. For administration instructions, see Dosage and Administration (2.3). Subsequent Doses: The dose should be increased in a stepwise fashion from 2 mg to 10 mg orally once daily to achieve the desired improvement of symptoms and/or flow rates. Doses of 10 mg once daily are generally required for a clinical response. Therefore, treatment with 10 mg for a minimum of 4 weeks to 6 weeks may be required to assess…
Everything below is the FDA label for Tezruly (solution). Terazosin is also sold as tablet and capsule, and those are different medicines to take — follow the label for the one you were prescribed.
Tezruly side effects
The following clinically significant adverse reactions are described elsewhere in the labeling: Syncope and ‘‘First-dose’’ Effect [see Warnings and Precautions (5.1)] Orthostatic Hypotension [see Warnings and Precautions (5.2)] Priapism [see Warnings and Precautions (5.3)] Intraoperative Floppy Iris Syndrome [see Warnings and Precautions (5.5)] In treatment of BPH, the most common adverse reactions (≥1% of patients and at a higher incidence than placebo) were asthenia, flu syndrome, postural hypotension, nausea, somnolence, vertigo, dyspnea, nasal congestion/rhinitis, blurred vision/amblyopia and erectile dysfunction. (6.1) In treatment of hypertension, the most common adverse reactions where the incidence on terazosin was ≥ 5%, where the incidence on terazosin was at least 2% and greater than placebo or where the reaction was of particular interest were asthenia, back pain, pain in the extremities, headache, palpitations, postural hypotension, tachycardia, nausea, edema, peripheral edema, weight gain, depression, dizziness, libido, decreased, nervousness, paresthesia, somnolence, dyspnea, nasal congestion, sinusitis, blurred vision, and erectile dysfunction. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact ANI Pharmaceuticals, Inc. at 1-855-204-1431 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical studies are conducted…
Who shouldn’t take Tezruly
TEZRULY is contraindicated in patients known to be hypersensitive to terazosin or any component of TEZRULY. Hypersensitivity to terazosin hydrochloride or any other ingredient in TEZRULY. (4)
Tezruly drug interactions
Co-administration of verapamil with terazosin increases the systemic exposure of terazosin [see Clinical Pharmacology (12.3)] , which may increase the risk of hypotenstion. To reduce the risk of hypotension, dosage reduction and re-titration of either agent may be necessary [see Warnings and Precautions (5.3)] . Co-administration of verapamil with terazosin increases the systemic exposure of terazosin and may lead to hypotension. Dosage reduction and re-titration of either agent may be necessary. (7)
Every terazosin product we track (2)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
| # | Drug | Rating | Type | Form | Generic? | Pharmacy pays | |
|---|---|---|---|---|---|---|---|
| 1 | 70/100 | Prescription | Tablet | Generic | $4 | View → | |
| 2 | 70/100 | Prescription | Solution | Generic | $4 | View → |
What terazosin pills look like
Imprint codes, colour and shape from the FDA’s labelling data. Match the imprint on your pill — or search any imprint.
| Imprint | Strength | Colour | Shape | Maker |
|---|---|---|---|---|
| TL383 | 1 mg | gray | capsule | — |
| AP783 | 5 mg | pink | capsule | — |
| AP784 | 10 mg | turquoise | capsule | — |
| AP781 | 1 mg | white | capsule | — |
| AP782 | 2 mg | yellow | capsule | — |
| TL384 | 2 mg | white | capsule | — |
| TL383 | 1 mg | gray | capsule | — |
| TL384 | 2 mg | white | capsule | — |
| TL385 | 5 mg | orange | capsule | — |
| TL386 | 10 mg | green | capsule | — |
| TL383 | 1 mg | gray | capsule | — |
Terazosin and breastfeeding
From LactMed, the US National Library of Medicine’s Drugs and Lactation Database — quoted, not rewritten.
Full LactMed record for terazosin: levels in milk, effects in breastfed infants, and the drugs it would consider insteadBecause no information is available on the use of terazosin during breastfeeding, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.
National Institute of Child Health and Human Development, record revised December 15, 2024. LactMed states its information is not a substitute for professional judgement.
What people report to the FDA about terazosin
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 1,394 reports naming terazosin, and the FDA flagged 73% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- dyspnoea115 reports
- fatigue80 reports
- constipation75 reports
- dizziness72 reports
- blood pressure increased71 reports
- diarrhoea68 reports
- pneumonia67 reports
- fall64 reports
Read these as a signal, not a rate. A report does not mean terazosin caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label section above.
Source: openFDA drug/event (FAERS), retrieved July 26, 2026.
Related calculators
Frequently asked questions
What is Tezruly?
Tezruly (Terazosin Hydrochloride) is an alpha-adrenergic blocker used to treat Hypertension, Prostatic Hyperplasia, Urinary Retention.
What kind of drug is terazosin?
The FDA classifies terazosin as an alpha-adrenergic blocker. Alpha-adrenergic blockers block the alpha-1 receptors that adrenaline-like signals use to tighten muscle in blood vessels and the prostate. This relaxes those muscles, lowering blood pressure and easing urine flow in men with an enlarged prostate. If you are checking whether it is safe to combine with something else, the class is what matters — two drugs from the same class usually should not be stacked.
Can you take terazosin with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run terazosin against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What brand names is terazosin sold under?
We track 2 terazosin-containing products in the U.S.: Hytrin and Tezruly. They are the same active ingredient; they differ in form, manufacturer, price and FDA recall record.
What forms does terazosin come in?
Across the brands we track, terazosin is currently marketed as tablet, capsule and solution, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic terazosin?
We do not currently list a generic-labelled terazosin product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.
Cite this page
- APA
- pharmaranks. (2026, July 24). Terazosin: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/terazosin
- MLA
- “Terazosin: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/terazosin.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for terazosin on DailyMed (NIH) ↗.